Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus

Fertility and Sterility

Volumn 69, Issue 2, 1998, Pages 252-257

  Petta, Carlos A ^a   Faundes, Anibal ^b   Dunson, Thomas R ^b   Ramos, Marsha ^b   DeLucio, Mara ^b   Faundes, Daniel ^b   Bahamondes, Luis ^b  

^a Center for Mother and Child Research of Campinas   (Brazil)

^b NONE

Author keywords

Backup contraception; Cervical mucus; Contraception; Depo Provera; Estradiol; Progesterone; Sperm penetration distance

Indexed keywords

MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MUCUS SECRETION; PRIORITY JOURNAL; SPERMATOZOON PENETRATION; UTERINE CERVIX MUCUS;

ACCEPTORS; ACCEPTORS, NEW--WOMEN; AMERICAS; BIOLOGY; BRAZIL; CERVICAL MUCUS; CERVIX; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE METHODS; CONTRACEPTIVE MODE OF ACTION; DEMOGRAPHIC FACTORS; DEPO-PROVERA--PHARMACODYNAMICS; DEVELOPING COUNTRIES; FAMILY PLANNING; FAMILY PLANNING PROGRAMS; GENITALIA; GENITALIA, FEMALE; INHIBITION OF FERTILIZATION; INJECTABLES; LATIN AMERICA; MEDROXYPROGESTERONE ACETATE--PHARMACODYNAMICS; PHYSIOLOGY; POPULATION; POPULATION DYNAMICS; RESEARCH METHODOLOGY; RESEARCH REPORT; SOUTH AMERICA; SPERM TRANSPORT INHIBITION; TIME FACTORS; UROGENITAL SYSTEM; UTERUS;

ADULT; CERVIX MUCUS; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MEDROXYPROGESTERONE 17-ACETATE; SPERMATOZOA; TIME FACTORS;

EID: 0031930955     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(97)00477-9     Document Type: Article

References (17)

1. Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust 1981;1(Suppl 1):1-20.
2. Siriwongse T, Snidvongs W, Tantayaporn P, Leepipatpaiboon S. Effect of depo-medroxyprogesterone acetate on serum progesterone levels, when administered on various cycle days. Contraception 1982;26:487-93.
3. Shelton JD, Angle MA, Jacobstein RA. Medical barriers to access to family planning. Lancet 1993;340:1334-5.
4. Curtis KM, Bright PL, editors. Technical Guidance Working Group. Recommendations for updating selected practices in contraceptive use: results of a technical meeting. Chapel Hill, NC: USAID, 1994.
5. Moghissi KS, Syner FN, Mcbride LC. Contraceptive mechanism of microdose norethindrone. Obstet Gynecol 1973;41:585-94.
6. World Health Organization. Laboratory manual for the examination of human semen; and sperm-cervical mucus interaction. New York: Cambridge University Press, 1993.
7. Dunson TR, Blumenthal PD, Alvarez F, Brache V, Cochon L, Dalberth B, et al. Timing of onset of contraceptive effectiveness in Norplant implant users: Part I. Changes in cervical mucus. Fertil Steril 1998;69:258-66.
8. Katz DF, Overstreet JW, Hanson FW. A new quantitative test for sperm penetration into cervical mucus. Fertil Steril 1980;33:179-86.
9. Irvin DS, Aitken RJ. Predictive value of in-vitro sperm function tests in the context of an AID service. Hum Reprod 1986;8:539-45.
10. Katz DF, Slade DA, Nakajima ST. Analysis of pre-ovulatory changes in cervical mucus hydration and sperm penetrability. Adv Contracept 1997;13:143-51.
11. Nygren KG, Lindberg P, Martinsson K, Bosu WTK, Johansson EDB. Radioimmunoassay of norethindrone. Peripheral plasma levels after oral administration to humans and rhesus monkeys. Contraception 1974;9:265-79.
12. Weiner E, Victor A, Johansson DB. Plasma levels of d-norgestrel after oral administration. Contraception 1976;14:563-70.
13. Alvarez F, Faúndes A, Johansson E, Coutinho E. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills. Fertil Steril 1983;40:120-3.
14. King RJB, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062-6.
15. Brache V, Faúndes A, Johansson E, Alvarez F. Anovulation, inadequate luteal phase and poor sperm penetration in cervical mucus during prolonged use of NORPLANT® implants. Contraception 1985;31:261-73.
16. Croxatto HB, Díaz S, Salvatierra AM, Morales P, Ebensperger C, Brandeis A. Treatment with NORPLANT® subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1992;36:193-201.
17. Moghissi KS, Syner FN, Evants TN. A composite picture of the menstrual cycle. Am J Obstet Gynecol 1972;114:405-18.